Novartis issues warning for breast cancer drug Femara

Share this article:

Novartis last week issued a warning that its breast cancer drug, Femara (letrozole), has been associated with birth defects, a caution prompted by reports that the drug was being used to help a woman become pregnant.
Femara is approved for use only in postmenopausal women with breast cancer. But there is evidence some doctors have prescribed it as a fertility treatment because it suppresses estrogen and can promote ovulation.
Novartis is sending letters to fertility doctors worldwide to reiterate a warning that the drug should not be given to women who may be pregnant, a company spokeswoman said in published reports.
The FDA has not taken any action, but a spokeswoman told the Associated Press that the agency was reviewing the matter. Novartis reportedly plans to send a letter to U.S. fertility specialists in coming days.

Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.